Clinical Trial Update: Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial assessing retinal ganglion cell function after intravitreal ranibizumab in diabetic macular edema has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Federal University of São Paulo | Conditions: Diabetic Macular Edema | Phase 4 | Status: WITHDRAWN